| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Total income and other revenues | $117.0M+2.5% | $114.2M-26.8% | $156.0M+109.0% | $74.6M+40.5% | $53.1M+179.7% | $19.0M-3.3% | $19.6M |
| Provision for changes in expected cash flows from financial royalty assets | -$295.8M-140.4% | $732.5M+30.6% | $560.7M-38.0% | $904.2M+99.7% | $452.8M+96.2% | $230.8M+122.6% | -$1.02B |
| Provision for credit losses on unfunded commitments | $89.0M | $0 | $0 | — | — | — | — |
| Research and development funding expense | $452.0M+22500.0% | $2.0M-96.2% | $52.0M-70.6% | $177.1M-11.5% | $200.1M+661.1% | $26.3M-68.3% | $83.0M |
| General and administrative expenses (includes $290,890, $3,224, and $3,302 of share-based compensation expense for the years ended December 31, 2025, 2024 and 2023, respectively; see Note 4) | $573.5M+142.3% | $236.7M-5.2% | $249.7M+9.9% | $227.3M+24.3% | $182.8M+0.6% | $181.7M+75.7% | $103.4M |
| Total operating expense, net | $818.7M-15.7% | $971.1M+12.6% | $862.4M-55.3% | $1.93B+124.8% | $858.7M+63.0% | $527.0M+165.1% | -$808.9M |
| Operating income | $1.56B+20.7% | $1.29B-13.4% | $1.49B+385.9% | $307.1M-78.5% | $1.43B-10.3% | $1.60B-39.2% | $2.62B |
| Equity in earnings of equity method investees | -$29.1M+1.8% | -$29.6M-2.5% | -$28.9M-421.9% | $9.0M-54.0% | $19.5M+143.8% | -$44.5M-236.7% | $32.5M |
| Interest expense | $307.7M+36.4% | $225.5M+20.5% | $187.2M-0.4% | $188.0M+13.1% | $166.1M+5.8% | $157.1M-41.5% | $268.6M |
| Losses on derivative financial instruments | $0-100.0% | $6.0M+162.0% | $2.3M+102.4% | -$96.6M-548.7% | $21.5M-48.8% | $42.1M+7.5% | $39.1M |
| Losses/(gains) on equity securities | $21.9M+155.3% | -$39.5M+54.6% | -$87.1M-360.6% | $33.4M-30.4% | $48.1M+119.5% | -$247.1M-58.6% | -$155.7M |
| Gains on available for sale debt securities | -$45.9M+70.4% | -$154.9M+32.9% | -$230.8M-3487.2% | $6.8M+138.2% | -$17.9M+4.0% | -$18.6M | $0 |
| Interest income | -$33.6M+29.0% | -$47.3M+34.5% | -$72.3M+7.7% | -$78.3M-46.3% | -$53.5M-88.6% | -$28.4M-27.1% | -$22.3M |
| Other non-operating expenses, net | $14.3M+839.1% | $1.5M-93.0% | $21.7M+47.3% | $14.8M+159.9% | $5.7M-82.7% | $32.8M+8451.4% | -$393K |
| Total other expense/(income), net | $235.3M+713.3% | -$38.4M+81.5% | -$207.9M-370.0% | $77.0M-59.4% | $189.5M+277.9% | -$106.6M-165.9% | $161.8M |
| Consolidated net income before tax | $1.32B-0.5% | $1.33B-21.7% | $1.70B+639.0% | $230.1M-81.5% | $1.24B-27.1% | $1.70B-30.9% | $2.46B |
| Income tax expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Consolidated net income | $1.32B-0.5% | $1.33B-21.7% | $1.70B+639.0% | $230.1M-81.5% | $1.24B-27.1% | $1.70B-30.9% | $2.46B |
| Net income attributable to non-controlling interests | $553.2M+17.3% | $471.8M-16.5% | $565.3M+201.9% | $187.2M-69.9% | $621.5M-14.5% | $726.9M+543.9% | $112.9M |
| Net income attributable to Royalty Pharma plc | $770.9M-10.2% | $859.0M-24.3% | $1.13B+2549.5% | $42.8M-93.1% | $619.7M-36.4% | $975.0M-58.5% | $2.35B |
| Basic (in dollars per share) | $1790.00-6.8% | $1920.00-24.4% | $2540.00+2440.0% | $100.00-93.3% | $1490.00+12.9% | $1320.00 | — |
| Diluted (in dollars per share) | $1780.00-6.8% | $1910.00-24.5% | $2530.00+2430.0% | $100.00-93.3% | $1490.00+12.9% | $1320.00 | — |
| Basic (in shares) | 429.8M-4.1% | 448.2M+0.1% | 447.6M+2.2% | 438.0M+5.6% | 414.8M+10.5% | 375.4M | — |
| Diluted (in shares) | 564.5M-5.0% | 594.1M-1.5% | 602.9M+37.7% | 438.0M+5.6% | 414.8M+10.5% | 375.5M | — |
| Income from financial royalty assets | |||||||
| Other royalty income and revenues | |||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.